The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

KU Hematology & Medical Oncology Review 2019
Avatar

KU ASCO 2019 Long-Term Survival of Dabrafenib Plus Trametinib in Metastic BRAF-Mutated Melanoma & PR and Survival of Neoadjuvant Therapy

By KU Hematology & Medical Oncology Review 2019 FEATURING Gary Doolittle
By KU Hematology & Medical Oncology Review 2019 FEATURING Gary Doolittle
0 views
August 22, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
Skin
12:46
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Update on Surgical Treatment of Melanoma & Adjuvant…

Feat. G. Doolittle
07:50
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Updates on Trial Discussing Nivolumab + Ipilimumab in M…

Feat. G. Doolittle
08:44
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Long-Term Survival of Dabrafenib Plus Trametinib in Met…

Feat. G. Doolittle